SGLT2-inhibitors (SGLT2-i) and DPP4-inhibitors (DPP4-i) are two commonly prescribed glucose-lowering treatment options [9], recommended after metformin in type 2 diabetes clinical guidelines [10]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.